Lung cancer affects non-smokers, with 25% of patients having never smoked, highlighting the need for awareness of persistent symptoms and environmental risk factors. Genetic testing is essential for ...
Biocartis’ Idylla EGFR Mutation Test has secured the EU Technical Documentation Assessment and Quality Management System certificate, making it the first Idylla Test to achieve Class C companion ...
Almost five new cases of lung cancer are diagnosed every minute globally and one of them would be a non-smoker. Screening gap remains one of the critical challenges of lung cancer prevention as most ...
February 2026 coverage highlighted combination EGFR therapy guidance, chemo-free treatment options, biomarker testing and ...
EGFR G719X 2 (1.3) No additional alterations detected (including one QC for RNAl) 2 EGFR L861Q 4 (2.7) No additional alterations detected 4 DNA and RNA were extracted from formalin-fixed ...
Targeted therapies are cancer medications that work more selectively than standard chemotherapy medications. They do this by targeting specific molecules or genetic changes in cancer cells in order to ...
Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results